Advertisement
Document › Details
Teneobio, Inc.. (6/8/20). "Press Release: Teneobio Enters a Research Collaboration and Licensing Agreement to Develop Next Generation Engineered Cell Therapies with Intellia Therapeutics". Newark, CA.
Organisation | Teneobio Inc. | |
Organisation 2 | Intellia Therapeutics Inc. (Nasdaq: NTLA) | |
Product | UniAbs™ (Human Heavy Chain Antibodies ) | |
Product 2 | T cell therapy | |
Person | Vafa, Omid (TeneoBio 201706 CBO) | |
Person 2 | Schiermeier, Andrew (Intellia Therapeutics 202106 EVP + COO before Merck (DE) 201504 Head Global Oncology) | |
Teneobio, Inc. announced that it has entered into a research collaboration and licensing agreement with Intellia Therapeutics, a CRISPR/Cas9 therapeutics company, to use Teneobio’s Heavy Chain Antibodies (UniAbs®) for Intellia’s next generation engineered cell therapies. In addition, Teneobio will use its proprietary platforms to discover novel UniAbs® against targets which can be used in engineered cell therapies for various life-threatening diseases. Intellia will have the option to exclusively license the novel antibodies for global development and commercialization.
Under the terms of the agreement, Teneobio will receive an upfront payment and will be eligible to receive additional payments based on achievement of certain clinical and regulatory milestones, as well as royalties on future potential sales.
Omid Vafa, Chief Business Officer at Teneobio, said, “We are excited to partner with Intellia, a pioneer of genome editing treatments. Together we aim to create the next generation of engineered cell therapies. Teneobio’s unique discovery platform rapidly identifies UniAbs with excellent developability profiles, enabling the engineering of modular multispecifics. These advantages will be valuable in creating next generation differentiated cellular therapies.”
Andrew Schiermeier, Chief Operating Officer at Intellia, added, “We believe that the combined power of Teneobio’s antibody discovery platform and Intellia’s proprietary approaches to T-cell engineering will accelerate the development of genome editing products for patients.”
About Teneobio, Inc.
Teneobio, Inc. is a clinical stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAb®), for the treatments of cancer, autoimmunity, and infectious diseases. Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies. TeneoSeek rapidly identifies large numbers of unique binding molecules specific for therapeutic targets of interest. Versatile antibody variable domains (UniDab®) derived from UniAb® can be assembled into multi-specific and multivalent therapeutic proteins, surpassing limitations of conventional antibody therapeutics. Teneobio’s “plug-and-play” T-cell engaging platform includes a diverse set of anti-CD3 antibodies for therapeutics with optimal efficacy and reduced toxicity.
Teneobio partners include AbbVie, Janssen, GSK, Kite and Poseida. For more information, please visit www.teneobio.com.
Company Inquiries for Teneobio, Inc.
Omid Vafa, Chief Business Officer
ovafa@teneobio.com
Record changed: 2023-06-05 |
Advertisement
More documents for Teneobio Inc.
- [1] Teneobio, Inc.. (2/11/19). "Press Release: AbbVie and TeneoBio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma". North Chicago, IL & Menlo Park, CA....
- [2] Selexis S.A.. (12/17/18). "Press Release: TeneoBio and Selexis Enter Second Services Agreement to Develop Research Cell Banks". Geneva & Menlo Park, CA....
- [3] Poseida Therapeutics, Inc.. (8/7/18). "Press Release: TeneoBio and Poseida Expand Their Partnership to Develop UniDabs for Advanced CAR-T Therapies". Menlo Park, CA & San Diego, CA....
- [4] Teneobio, Inc.. (7/9/18). "Press Release: TeneoBio Announces Research Collaboration with Janssen to Develop Multispecific Antibodies for Oncology". Menlo Park, CA....
- [5] Teneobio, Inc.. (1/8/18). "Press Release: TeneoBio Announces a Strategic Alliance with Tesaro to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies". Menlo Park, CA....
- [6] Selexis S.A.. (6/12/17). "Press Release: Selexis SA and TeneoBio, Inc. Team Up to Advance the Development of UniAbs Targeting Cancer". Geneva & Menlo Park, CA....
- [7] Teneobio, Inc.. (5/22/17). "Press Release: TeneoBio and Poseida Announce License Agreement for the Use of UniDab in CAR T-Cell Therapy". Menlo Park, CA & San Diego, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top